4000-Protein Surrogates with a Median Time-To-Event Prediction of 1.7 Years for High-Risk Individuals

SAN FRANCISCO, CALIFORNIA, UNITED STATES, September 8, 2022 /EINPresswire.com/ -- U.S. and Hong Kong-based Rainbow Genomics launches a proteomics-based test to assess 4-year likelihood of myocardial infarction (heart attack) in both asymptomatic individuals and at-risk patients. The test characterizes a core group of 25 proteins directly associated with heart attack, supplemented by the analysis of an additional 3975 proteins that provide related indications associated with a wide range of cardio and metabolic abnormalities.

This test may be beneficial for patients who may remain at risk even when their low-density lipoprotein (LDL) and blood pressure are considered under control via medications, or for elderly individuals without a diagnosis of cardiovascular disease. The test is provided as a “research use only” product, enabling clinicians and researchers to characterize the near-term residual cardiovascular risks not captured in coronary artery disease workup.

Only a regular blood sample is needed for this test. The testing process is performed at a U.S. CLIA-certified and CAP-accredited laboratory. The test results are reviewed by a board-certified medical director. The test report is issued by a dual MD and PhD degree holding medical director.

This test is available for clinics and hospitals who may provide a batch of patient samples at a time. It is not currently available for single patient testing. For more information, please contact us at info@rainbowgenomics.com

About Rainbow Genomics

Rainbow Genomics (www.rainbowgenomics.com) is committed to providing clinically-validated genomic and proteomic testing to Asian, Caucasian, mixed-race, and local minority populations. The company delivers high diagnostic success for physicians, enabling timely treatment for patients that can benefit from immediate medical interventions.

Utilizing a multi-technology-platform approach, including proteomics, whole genome, whole exome, RNA, long-read, methylation, single cell and Sanger sequencing, high-resolution microarray testing, and high-density DNA array genotyping, and through multiple international collaborations, Rainbow Genomics delivers a diagnostic yield meeting or exceeding the highest standards reported by leading U.S. and European medical institutions.

All Rainbow Genomics tests are performed in CLIA-certified and CAP-accredited high-complexity clinical laboratories. Patient privacy is protected by Rainbow’s HIPAA-compliant clinical testing process.

DANIEL SIU
Rainbow Genomics
3481 0977
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.